Galectin Therapeutics will participate in the 20th edition of the Discovery on Target meeting, the industry’s preeminent event on Novel Drug Targets and Technologies. The Company will present an update on its belapectin liver cirrhosis program during the Fibrosis and Inflammation session. The presentation, titled “Targeting Activated Macrophages to Improve Liver Cirrhosis: The Discovery and Clinical Translation of Belapectin,” will take place Wednesday, September 27, at 2:25 PM EDT and will be delivered by Dr. Pol F. Boudes, M.D., Chief Medical Officer of Galectin Therapeutics. Boudes commented: “The role of activated macrophages in the establishment and progression of liver cirrhosis is predominant. These cells, when activated, invade the liver, and produce galectin-3, a pro-inflammatory and pro-fibrotic molecule. Belapectin is a galectin-3 inhibitor that, thanks to its unique molecular structure, is captured by activated macrophages and can inhibit galectin-3 at its site of production. Liver cirrhosis has been a field that has been neglected for far too long by drug developers and the Discovery on Target meeting is an excellent opportunity to familiarize a large audience to the consequences of liver cirrhosis and portal hypertension and highlight the opportunity our belapectin program offers for patients affected by this severe disease.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GALT:
- Galectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023
- Galectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023
- Galectin Therapeutics to Present Data on Liver Cirrhosis at the 9th Edition of the Paris NASH meeting, at Institut Pasteur, September 7th & 8th 2023
- Galectin Therapeutics to present data on liver cirrhosis at NASH meeting
- Galectin Therapeutics reports Q2 EPS (15c) vs (16c) last year